Approval Number : 国药准字H20065189 国药准字H20065190
Naloxone hydrochloride was synthesized in 1960 and is a derivative of hydroxy(dihydro)ketomorphine. Naloxone is an opioid receptor antagonist and was initially used to counteract opioid overdose. It has the specific effect of reversing respiratory depression and inducing awakening. It is a highly effective antidote for opioid overdose and a diagnostic drug for morphine and heroin dependence. Based on studies of the physiological effects of endogenous opioid-like substances, clinical researchers have not only used naloxone to antagonize respiratory depression caused by opioid drugs but have also conducted trials on stress-related diseases such as non-anesthetic drug overdose (ethanol, benzodiazepines), shock, cerebral infarction, and neonatal asphyxia syndrome, achieving good therapeutic results and generating great interest among doctors both domestically and internationally. In recent years, clinicians at home and abroad have also used it for the treatment of acute alcohol and sedative poisoning, hepatic encephalopathy, cerebral infarction, post-asphyxial ischemic encephalopathy in neonates, severe heatstroke, acute and chronic respiratory failure, and various critical conditions, with good results.
Detail
Approval Number : 国药准字H20040593
Matrine for Injection is an active ingredient extracted from the traditional Chinese medicinal herbs Sophora flavescens and Sophora root. Basic research has shown that it has antiviral, anti-liver fibrosis, anti-apoptotic (preventing liver cell death), cell membrane stabilization, immunomodulatory, adenosine triphosphatase activation, induction of hepatic microsomal drug-metabolizing enzymes, hepatoprotective, and antioxidant effects. It can also increase bile flow and alleviate jaundice. It has broad prospects for primary applications, particularly in antiviral, anti-liver fibrosis, liver protection, liver enzyme regulation, and jaundice reduction.
Detail
Approval Number : 国药准字H20040594
Matrine for Injection is an active ingredient extracted from the traditional Chinese medicinal herbs Sophora flavescens and Sophora root. Basic research has shown that it has antiviral, anti-liver fibrosis, anti-apoptotic (preventing liver cell death), cell membrane stabilization, immunomodulatory, adenosine triphosphatase activation, induction of hepatic microsomal drug-metabolizing enzymes, hepatoprotective, and antioxidant effects. It can also increase bile flow and alleviate jaundice. It has broad prospects for primary applications, particularly in antiviral, anti-liver fibrosis, liver protection, liver enzyme regulation, and jaundice reduction.
Detail
Approval Number : 国药准字H20080551 国药准字H20080629 国药准字H20080552
Naloxone hydrochloride, synthesized in 1960, is a derivative of hydroxy (di)morphinone. Naloxone is an opioid receptor antagonist primarily used to counteract opioid overdose. It has respiratory stimulant and awakening effects, making it an effective antidote for opioid overdose and a diagnostic tool for opioid and heroin dependence. Building on the research of endogenous opioid-like substances\' physiological effects, clinical practitioners have found success in using naloxone not only to reverse opioid-induced respiratory depression but also in the treatment of non-anesthetic drug overdose (such as alcohol and benzodiazepines), shock, cerebral infarction, neonatal asphyxia syndrome, and other stress-related disorders. This has garnered significant interest among medical professionals both domestically and internationally. In recent years, clinicians have also utilized naloxone in the treatment of acute alcohol and sedative poisoning, hepatic encephalopathy, cerebral infarction, post-asphyxial ischemic encephalopathy in neonates, severe heatstroke, acute and chronic respiratory failure, as well as various critical shock conditions, all with positive outcomes.
Detail
Approval Number : 国药准字H20050530
The Norfloxacin Injection developed by our company is a third-generation quinolone antibiotic. It is a new formulation improved from the original Gluconate Norfloxacin Injection. This variety utilizes the novel auxiliary material, instant salt formation technology, which effectively solves the problem of polymerization reaction products in infusion products. Extensive pharmacological and toxicological studies have been conducted, demonstrating that its quality, manufacturing process, and safety are superior to the already marketed Gluconate Norfloxacin Injection. Our company has applied for a patent for this new auxiliary material. Therefore, the Norfloxacin Injection developed by our company is a completely unique product that is distinct from Gluconate Norfloxacin Injection.
Detail
Approval Number :
Fasudil Hydrochloride Injection inhibits the phosphorylation of myosin light chains in the final stage of smooth muscle contraction, leading to vasodilation. It has demonstrated relief and prevention of cerebral vasospasm in dogs through two intracranial injections of autologous blood, and intravenous administration of fasudil hydrochloride can alleviate cerebral vasospasm. Early continuous administration can prevent the occurrence of cerebral vasospasm. It improves cerebral cortical blood flow in a delayed cerebral vasospasm model in dogs. In a rat model of cerebral ischemia induced by bilateral carotid artery occlusion, it increases local cerebral blood flow in the ischemic region. In patients with decreased cerebral blood flow, positron emission tomography (PET) has shown an increase in blood flow in the ischemic region. It also partially increases brain regional glucose utilization in a rat model of cerebral ischemia induced by bilateral carotid artery occlusion. It exhibits inhibitory effects on delayed neuronal cell damage in a sand rat model of cerebral ischemia induced by transient bilateral carotid artery occlusion. The mechanism of action (in vitro experiments) involves inducing relaxation of isolated cerebral blood vessels. It inhibits the vasoconstrictive effect caused by calcium ions in isolated blood vessels. It inhibits vasoconstriction caused by various cerebral vasoconstrictive agents. It inhibits the phosphorylation of myosin light chains during vascular constriction without reducing intracellular calcium levels. It also inhibits myosin light chain phosphorylation enzymes under conditions similar to those in the body.
Detail
Approval Number : 国药准字H20055299 国药准字H20055300
This product is a structural analog of deoxyguanosine and can inhibit the replication of herpes viruses. Its mechanism of action involves ganciclovir being initially phosphorylated by a protein kinase homolog encoded by the UL97 gene of cytomegalovirus (CMV) to form a monophosphate salt. It is further phosphorylated into diphosphate and triphosphate forms by cellular kinases. In CMV-infected cells, the concentration of triphosphate is 100 times higher than that in uninfected cells, indicating that the product is preferentially phosphorylated in infected cells. Once ganciclovir is in the triphosphate form, it can persist in CMV-infected cells for several days. The triphosphate form of ganciclovir inhibits viral DNA synthesis by competitively inhibiting viral DNA polymerase and incorporating into the DNA of both the virus and host cells, leading to termination of viral DNA elongation. Ganciclovir exhibits stronger inhibition on viral DNA polymerase compared to host polymerase.
Detail
Approval Number : 国药准字H14023718
Methochloride hydrochloride promotes the oxidative-reductive metabolism of brain cells and increases the utilization of carbohydrates. It has stimulating effects on patients with central inhibition.
Detail
Approval Number : 国药准字H20030398
Bioenergy is stored in the form of high-energy phosphate bonds in adenosine triphosphate (ATP). The synthesis of ATP primarily relies on ATP synthase within the mitochondria. ATP synthase utilizes the electrochemical potential generated by the mitochondrial respiratory chain as an energy source to phosphorylate ADP and synthesize ATP. Therefore, the metabolic process of energy synthesis is the oxidative phosphorylation process carried out by mitochondria. Maintaining the normal physiological function of mitochondria is essential for energy synthesis and metabolism. Based on the latest research in energy metabolism pharmacology and the practical needs of clinical medicine and research, the development of Adenosine Chloride Sodium Injection has brought new treatment approaches to healthcare professionals. It has unique efficacy in the rescue and rehabilitation treatment of cardiovascular and cerebrovascular diseases, protective treatment for various liver diseases, and nutritional support for cancer patients. Additionally, it is a new convenient intravenous infusion formulation that reduces the risk of infection, fully meeting the clinical needs for the treatment of various acute and chronic diseases.
Detail
Approval Number : 国药准字H4023717
Methochloride hydrochloride promotes the oxidative-reductive metabolism of brain cells and increases the utilization of carbohydrates. It has stimulating effects on patients with central inhibition.
Detail